Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. Exelixis, Inc. has collaboration and license agreement with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Merck, Invenra, Inc., StemSynergy Therapeutics, Inc., and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
Phone650-837-7000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$853.83 million
Profitability
Miscellaneous
Employees484
Next Earnings Date5/1/2019 (Estimated)
OptionableOptionable
Exelixis (NASDAQ:EXEL) Frequently Asked Questions
What is Exelixis' stock symbol?
Exelixis trades on the NASDAQ under the ticker symbol "EXEL."
How were Exelixis' earnings last quarter?
Exelixis, Inc. (NASDAQ:EXEL) issued its earnings results on Tuesday, February, 12th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.23 by $0.14. The biotechnology company earned $228.60 million during the quarter, compared to analysts' expectations of $188.44 million. Exelixis had a return on equity of 48.90% and a net margin of 80.95%. The firm's quarterly revenue was up 90.4% on a year-over-year basis. During the same period in the prior year, the business earned $0.12 EPS. View Exelixis' Earnings History.
When is Exelixis' next earnings date?
What price target have analysts set for EXEL?
10 equities research analysts have issued twelve-month target prices for Exelixis' stock. Their forecasts range from $22.00 to $48.00. On average, they expect Exelixis' stock price to reach $29.10 in the next twelve months. This suggests a possible upside of 25.3% from the stock's current price. View Analyst Price Targets for Exelixis.
What is the consensus analysts' recommendation for Exelixis?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last year. There are currently 4 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Exelixis.
Has Exelixis been receiving favorable news coverage?
Headlines about EXEL stock have been trending somewhat negative on Sunday, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Exelixis earned a news impact score of -1.4 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future.
Are investors shorting Exelixis?
Exelixis saw a drop in short interest during the month of February. As of February 28th, there was short interest totalling 15,548,003 shares, a drop of 8.8% from the February 15th total of 17,054,642 shares. Based on an average trading volume of 3,134,824 shares, the days-to-cover ratio is presently 5.0 days. Currently, 5.3% of the shares of the stock are short sold. View Exelixis' Current Options Chain.
Who are some of Exelixis' key competitors?
Some companies that are related to Exelixis include Iqvia (IQV), Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), Intrexon (XON), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX), STARPHARMA HOLD/S (SPHRY), Pieris Pharmaceuticals (PIRS) and Anavex Life Sciences (AVXL).
What other stocks do shareholders of Exelixis own?
Who are Exelixis' key executives?
Exelixis' management team includes the folowing people:
- Dr. Stelios Papadopoulos, Co-Founder & Chairman (Age 71)
- Dr. Michael M. Morrissey, CEO, Pres & Director (Age 58)
- Mr. Christopher J. Senner, Exec. VP & CFO (Age 51)
- Dr. Peter Lamb, Exec. VP of Scientific Strategy & Chief Scientific Officer (Age 58)
- Mr. Jeffrey J. Hessekiel, Exec. VP, Gen. Counsel & Sec. (Age 50)
Who are Exelixis' major shareholders?
Exelixis' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (10.23%), FMR LLC (7.13%), First Trust Advisors LP (1.86%), Bank of New York Mellon Corp (1.25%), Geode Capital Management LLC (1.01%) and Geode Capital Management LLC (1.01%). Company insiders that own Exelixis stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Stelios Papadopoulos and Vincent T Marchesi. View Institutional Ownership Trends for Exelixis.
Which major investors are selling Exelixis stock?
EXEL stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Millennium Management LLC, American Century Companies Inc., D. E. Shaw & Co. Inc., Rhenman & Partners Asset Management AB, Tekla Capital Management LLC, Los Angeles Capital Management & Equity Research Inc. and Hsbc Holdings PLC. Company insiders that have sold Exelixis company stock in the last year include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, Gisela Schwab, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Stelios Papadopoulos and Vincent T Marchesi. View Insider Buying and Selling for Exelixis.
Which major investors are buying Exelixis stock?
EXEL stock was purchased by a variety of institutional investors in the last quarter, including Norges Bank, Oregon Public Employees Retirement Fund, Fiera Capital Corp, Prudential Financial Inc., First Trust Advisors LP, Samlyn Capital LLC, Bank of New York Mellon Corp and Frontier Capital Management Co. LLC. View Insider Buying and Selling for Exelixis.
How do I buy shares of Exelixis?
Shares of EXEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Exelixis' stock price today?
One share of EXEL stock can currently be purchased for approximately $23.22.
How big of a company is Exelixis?
Exelixis has a market capitalization of $6.97 billion and generates $853.83 million in revenue each year. The biotechnology company earns $690.07 million in net income (profit) each year or $1.43 on an earnings per share basis. Exelixis employs 484 workers across the globe.
What is Exelixis' official website?
How can I contact Exelixis?
Exelixis' mailing address is 1851 Harbor Bay Parkway, Alameda CA, 94502. The biotechnology company can be reached via phone at 650-837-7000 or via email at [email protected]
MarketBeat Community Rating for Exelixis (NASDAQ EXEL)
MarketBeat's community ratings are surveys of what our community members think about Exelixis and other stocks. Vote "Outperform" if you believe EXEL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EXEL will underperform the S&P 500 over the long term. You may vote once every thirty days.
